News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Orgenesis Enters Into R&D Agreement With the Fraunhofer IGB



11/12/2012 9:58:01 AM

WHITE PLAINS, N.Y.--(BUSINESS WIRE)--Orgenesis Inc. (OTCBB:ORGS) (“Orgenesis” or the “Company”), a development-stage company with a novel therapeutic technology dedicated to converting a patient’s own liver cells into functioning insulin-producing cells as a treatment for diabetes, announced today that it has entered into a service agreement (the “Agreement”) with the Fraunhofer Institute for Interfacial Engineering and Biotechnology (“Fraunhofer IGB”), a leading German contract research and development center for regenerative medicine.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES